Passage Bio Inc expected to post a loss of 31 cents a share - Earnings Preview

Passage Bio

02/08/2024 17:42

* Passage Bio Inc  PASG.OQ   PASG.O  is expected to show no
change
in quarterly revenue when it reports  results on August 5
(estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Passage Bio Inc is for a
loss
of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Passage Bio
Inc
is $5.50​, above​ its last closing price of $0.95. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.36       -0.36      -0.30     Beat    16.1
 Dec. 31 2024  -0.40       -0.40      -0.30     Beat    25.3
 Sep. 30 2023  -0.47       -0.46      -0.49     Missed  -7.4​
 Jun. 30 2023  -0.47       -0.48      -0.44     Beat    8
 ​​Mar.        -0.50       -0.50      -0.63     Missed  -27.2
 31 2023                                                
 Dec. 31 2022  -0.51       -0.52      -0.49     Beat    6.3​
 Jan. 1 0001   -0.74       -0.79      -0.49     Beat    38
 Jun. 30 2022  -0.79       -0.83      -0.73     Beat    11.7
 This summary was machine generated August 2 at 16:42 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)